FRE - Fresenius SE & Co. KGaA
XETRA
->
Healthcare
->
Medical Care Facilities
Bad Homburg vor der Höhe,
Germany
Type: Equity
FRE price evolution
FRE
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $3817 | $3852 | $4028 | $3673 |
| Inventory | $2549 | $2656 | $2639 | $2517 |
| Total current assets | $11227 | $11943 | $11339 | $12520 |
| Long term investments | ||||
| Property, plant & equipment | $9699 | $9863 | $10797 | $10782 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $42368 | $43513 | $44283 | $45284 |
| Current liabilities | ||||
| Accounts payable | $1220 | $1338 | $1251 | $1488 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $8278 | $9246 | $8376 | $6638 |
| Long term debt | $11469 | $11530 | $12712 | $17828 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $23541 | $24479 | $24840 | $26285 |
| Shareholders' equity | ||||
| Retained earnings | $18540 | $18217 | $18712 | $18418 |
| Other shareholder equity | -$121 | $254 | $168 | $18999 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2764 | $1837 | ||
| Short term investments | $184 | $200 | ||
| Net receivables | $9125 | $9308 | $8695 | |
| Inventory | $4833 | $4218 | $3945 | |
| Total current assets | $18279 | $17461 | $15772 | |
| Long term investments | $1410 | $1397 | ||
| Property, plant & equipment | $18841 | $18583 | $17603 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $76415 | $71962 | $66646 | |
| Current liabilities | ||||
| Accounts payable | $2070 | $2131 | $1883 | |
| Deferred revenue | ||||
| Short long term debt | $1091 | $2654 | ||
| Total current liabilities | $13658 | $15062 | $13216 | |
| Long term debt | $24727 | $16625 | $16821 | |
| Total noncurrent liabilities | $22243 | |||
| Total debt | ||||
| Total liabilities | $56000 | $42674 | $40623 | |
| Shareholders' equity | ||||
| Retained earnings | $19445 | $14860 | $13535 | |
| Other shareholder equity | $407 | -$446 | -$1135 | |
| Total shareholder equity | $18998 | $16949 | ||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $5704 | $5678 | ||
| Cost of revenue | ||||
| Gross Profit | $1406 | $1297 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $847 | $1212 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $125 | $165 | ||
| Interest expense | -$145 | -$137 | ||
| Net income | ||||
| Net income | $278 | -$614 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $22299 | $40840 | $36277 | |
| Cost of revenue | $25961 | |||
| Gross Profit | $5058 | $10725 | $10316 | |
| Operating activities | ||||
| Research & development | $758 | |||
| Selling, general & administrative | $5235 | |||
| Total operating expenses | $3915 | $7379 | $31803 | |
| Operating income | $4474 | |||
| Income from continuing operations | ||||
| EBIT | $4474 | |||
| Income tax expense | $477 | $697 | $903 | |
| Interest expense | -$428 | -$507 | -$752 | |
| Net income | ||||
| Net income | -$594 | $1372 | $1707 | |
| Income (for common shares) | $1707 | |||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$167 | -$50 | -$48 | -$1340 |
| Financing activities | ||||
| Dividends paid | -$550 | |||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$2337 | -$2022 | -$1481 | $296 |
| Effect of exchange rate | -$13 | -$7 | $1 | -$43 |
| Change in cash and equivalents | -$1068 | -$1455 | -$1543 | $1044 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $1818 | $1707 | ||
| Operating activities | ||||
| Depreciation | $2464 | $2573 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $5078 | $6549 | ||
| Investing activities | ||||
| Capital expenditures | -$2047 | -$2406 | ||
| Investments | -$7 | -$33 | ||
| Total cash flows from investing | -$1340 | -$2607 | -$2817 | -$3011 |
| Financing activities | ||||
| Dividends paid | -$550 | -$890 | -$491 | -$468 |
| Sale and purchase of stock | ||||
| Net borrowings | -$398 | -$1695 | ||
| Total cash flows from financing | $296 | -$1604 | -$1452 | -$3117 |
| Effect of exchange rate | -$43 | -$2 | $118 | -$238 |
| Change in cash and equivalents | $1044 | -$15 | $927 | $183 |
News
Fundamentals
| Market cap | $27.58B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 563.24M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.36 |
| Quick ratio | 1.05 |